Welcome to our dedicated page for Zivo Bioscience news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience stock.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a biotechnology innovator focused on developing natural bioactive compounds derived from proprietary algal strains. This page serves as the definitive source for all official company announcements, research milestones, and strategic developments.
Investors and industry stakeholders will find timely updates including financial results, partnership agreements, regulatory filings, and scientific advancements. Our curated news feed provides essential insights into ZIVO's progress in nutraceutical research and biotech applications.
The page organizes content by key categories: quarterly earnings disclosures, product development breakthroughs, intellectual property updates, and corporate governance matters. Each news item is presented with clear context to help users assess material developments.
Bookmark this resource for streamlined tracking of Zivo Bioscience's advancements in algal-based biotechnology. Check regularly for verified updates directly from company filings and authorized communications.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) announced a $1 million unsecured loan from its CEO, John Payne, to support working capital and a validation study for its coccidiosis treatment for broiler chickens. The loan has a 10% interest rate and includes warrants for 390,000 shares at $2.91 each. The company aims to validate its immune-modulating product, with results expected by mid-2023. Payne expressed confidence in Zivo's team and strategies, while CFO Keith Marchiando emphasized the significance of this support for funding beyond the current study. Zivo also continues to scale up production for the human food industry, showcasing its commitment to both animal and human health avenues.
Zivo Bioscience (NASDAQ: ZIVO) announced disappointing results from a recent study on a novel immune-modulating product for coccidiosis treatment in broiler chickens, conducted by a third party. The trial faced a significantly higher than usual mortality rate due to an intense disease challenge, yielding results not reflective of commercial production conditions. Despite this setback, ZIVO remains confident in its product's potential and plans to conduct a new study, expected to conclude by mid-year. The company continues to prioritize coccidiosis treatment while exploring additional health benefits from its proprietary algal cultures.
Zivo Bioscience has announced the formation of a wholly-owned subsidiary, ZIVOLife, which will hold an exclusive worldwide limited license to utilize the company's intellectual property for producing and supplying whole biomass algal products. This strategic move aims to enhance its corporate structure, capitalize on agtech market opportunities, and expedite revenue generation. Upon finalizing a license agreement, Zivo is set to receive royalty payments from ZIVOLife. A conference call is planned for early November to discuss these developments.